dChan - Q Origins Project Archive

Background:

Over the past two decades, my company – M·CAM – has been monitoring possible violations of the 1925 Protocol for

the Prohibition of the Use in War of Asphyxiating, Poisonous, or other Gases, and of Bacteriological Methods of Warfare

(the Geneva Protocol) 1972 Convention on the Prohibition of the Development, Production, and Stockpiling of

Bacteriological and Toxin Weapons and Their Destruction (the BTWC). In our 2003-2004 Global Technology

Assessment: Vector Weaponization M·CAM highlighted China’s growing involvement in Polymerase Chain Reaction

(PCR) technology with respect to joining the world stage in chimeric construction of viral vectors. Since that time, on a

weekly basis, we have monitored the development of research and commercial efforts in this field, including, but not

limited to, the research synergies forming between the United States Centers for Disease Control and Prevention (CDC),

the National Institutes for Allergies and Infectious Diseases (NIAID), the University of North Carolina at Chapel Hill (UNC),

Harvard University, Emory University, Vanderbilt University, Tsinghua University, University of Pennsylvania, many other

research institutions, and their commercial affiliations.

The National Institute of Health’s grant AI23946-08 issued to Dr. Ralph Baric at the University of North Carolina at

Chapel Hill (officially classified as affiliated with Dr. Anthony Fauci’s NIAID by at least 2003) began the work on

synthetically altering the Coronaviridae (the coronavirus family) for the express purpose of general research, pathogenic

enhancement, detection, manipulation, and potential therapeutic interventions targeting the same. As early as May 21,

2000, Dr. Baric and UNC sought to patent critical sections of the coronavirus family for their commercial benefit.1

In one

of the several papers derived from work sponsored by this grant, Dr. Baric published what he reported to be the full

length cDNA of SARS CoV in which it was clearly stated that SAR CoV was based on a composite of DNA segments.

“Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of

the SARS-CoV Urbani strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV)

that contained the expected marker mutations inserted into the component clones.”2 On April 19, 2002 – the Spring before the first SARS outbreak in Asia – Christopher M. Curtis, Boyd Yount, and Ralph

Baric filed an application for U.S. Patent 7,279,372 for a method of producing recombinant coronavirus. In the first

public record of the claims, they sought to patent a means of producing, “an infectious, replication defective,

coronavirus.” This work was supported by the NIH grant referenced above and GM63228. In short, the U.S. Department

of Health and Human Services was involved in the funding of amplifying the infectious nature of coronavirus between

1999 and 2002 before SARS was ever detected in humans.

https://f.hubspotusercontent10.net/hubfs/8079569/The%20FauciCOVID-19%20Dossier.pdf